Eli Lilly Announced The Results Of Two Phase 3 Tirzepatide Studies In Adults With Obesity With Weight-related Comorbidities, Excluding Type 2 Diabetes. SURMOUNT-3, SURMOUNT-4 Met All Primary And Key Secondary Objectives For Tirzepatide Compared To Placebo
Portfolio Pulse from Benzinga Newsdesk
Eli Lilly has announced the successful results of two Phase 3 studies for Tirzepatide in adults with obesity and weight-related comorbidities, excluding Type 2 diabetes. The studies, SURMOUNT-3 and SURMOUNT-4, met all primary and key secondary objectives compared to placebo.
July 27, 2023 | 10:51 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Eli Lilly's successful results from Phase 3 studies of Tirzepatide could potentially boost the company's stock in the short term.
The successful results of the Phase 3 studies for Tirzepatide indicate that the drug is closer to approval and market release. This could potentially increase Eli Lilly's revenues and positively impact its stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100